ClinicalTrials.gg
RecruitingNCT06527183FIBRO-NEPUpdated Sep 10, 2025

Fibromyalgia and Small Fiber Neuropathy

An observational study in Chronic Pain Syndrome, sponsored by Hospital Ambroise Paré Paris. Recruiting at 2 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Hospital Ambroise Paré Paris · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 135 studies in Chronic Pain with a site in France — 35 open to participants now, 39 under way, 2 of them phase 3. Chronic Pain · France.

Planned enrollment
36th of 68
150 · median 160
Started
2022
with 9 others
Observational
68 of 135
15 open now
Primary completion
2025-12
later than 3 of 38 live
Registered
112th of 135
by date
Lead sponsor
4 of 135
Hospital Ambroise Paré Paris

Among the 135 studies in Chronic Pain with a site in France, this one is the 36th largest by planned enrollment of the 68 observational ones that give a count, is one of 10 that started in 2022, is one of 68 observational ones, reaches primary completion later than 3 of the 38 other live ones, and was the 112th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

35 of the 135 studies in Chronic Pain with a site in France are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 135 studies in Chronic Pain with a site in France, or all of them as a file.
02

Study summary

The primary objective of this study will be to assess the proportion of fibromyalgia patients with diffuse small-fiber neuropathy (i.e. in the upper and lower limbs) and compare this proportion to patients with other chronic pains (nociplastic, nociceptive) and with healthy controls. Our analysis will be based on the demonstration of structural abnormalities of small nerve fibers by means of skin biopsy, but also of functional abnormalities using four validated tests commonly used in this field: quantitative sensory testing (QST), laser evoked potential recordings, Sudoscan and confocal corneal microscopy. It will thus be possible to verify whether or not patients with small fiber neuropathy have a particular clinical profile in terms of pain, physical activity, comorbidities or pain impact.

Read the detailed description

Small fiber neuropathy has been observed in a large proportion of fibromyalgia patients. However, the pathophysiological role of these neurological abnormalities in determining the pain and other symptoms of fibromyalgia, and the specificity of these abnormalities, are not well understood.

The primary objective of this study will be to assess the proportion of fibromyalgia patients with diffuse small-fiber neuropathy (i.e. in the upper and lower limbs) and compare this proportion to patients with other chronic pains (nociplastic, nociceptive) and with healthy controls. Our analysis will be based on the demonstration of structural abnormalities of small nerve fibers by means of skin biopsy, but also of functional abnormalities using four validated tests commonly used in this field: quantitative sensory testing (QST), laser evoked potential recordings, Sudoscan and confocal corneal microscopy. It will thus be possible to verify whether or not patients with small fiber neuropathy have a particular clinical profile in terms of pain, physical activity, comorbidities or pain impact.

03

Conditions studied

  • Chronic Pain Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with fibromyalgia, other chronic pains (nociplastic or nociceptive) and healthy subjects

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients over 18 years of age with no age limit -
  • having given their signed consent to take part in the study
  • affiliated to the French social security system
  • able to be followed for the entire duration of the study
  • reading and understanding French
  • accepting the principle of the study and able to comply with its conditions
  • suffering from chronic pain for at least six months of at least moderate intensity (≥ 4/10)
  • fibromyalgia detected by the FiRST questionnare and defined by the revised diagnostic criteria of the WHO or chronic nociceptive or nociplastic pain without associated fibromyalgia.
  • chronic pain for at least 6 months of at least moderate intensity (≥ 4/10)
  • untreated or with stable analgesic treatment for at least 2 weeks prior to inclusion- normal neurological examination at inclusion

Exclusion criteria

Exclusion Criteria:

  • litigation or compensation-seeking
  • cancer for less than 2 years
  • known cause of small-fiber neuropathy such as diabetes, systemic disease, hypothyroidism, alcohol, renal failure, genetic disease
  • clinical or EMG neuropathy
  • peripheral or central nervous system pathology with or without associated neuropathic pain
  • uncontrolled chronic pathology such as : morbid obesity, sleep apnea, uncontrolled hypertension, etc. - psychosis, previous suicide attempt
  • drug or psychoactive substance abuse
  • cognitive or psychological disorders incompatible with compliance with and/or understanding of the protocol
  • participation in another biomedical research protocol.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with fibromyalgia

    Patients with fibromyalgia based on ACR criteria

    Diagnostic Test: Skin punch biopsy to demonstrate small fiber neuropathy

  • Patients with other chronic pain (paired for the other groups)

    Patients with chronic pain other than fibromyalgia and neuropathic pain, eg nociplastic pains or nociceptive pains

    Diagnostic Test: Skin punch biopsy to demonstrate small fiber neuropathy

  • Paired healthy subjects

    Healthy subjects paired for gender and age

    Diagnostic Test: Skin punch biopsy to demonstrate small fiber neuropathy

Interventions

  • Diagnostic testSkin punch biopsy to demonstrate small fiber neuropathy

    Skin punch biopsy to assess intrapidermal nerve fiber density

    Also known as: Other diagnostic tests will include laser evoked potentiels, quantitative sensory testing, sudoscan, and confocal corneal microscopu

06

What researchers measure

Primary outcomes

  1. Prevalence of small fiber neuropathy or pathology as assessed with skin punch biopsy in patients with fibromyalgia as compared to patients with other chronic pains and healthy subjects

    intraepidermal nerve fiber density

    Time frame: Baseline and at 6 months

Secondary outcomes

  1. Correlation between intraepidermal nerve fiber density and pain or other patient reported outcome measures (quality of life, distress, disability...)

    Correlation statistics (Spearman Rho)

    Time frame: Baseline and at 6 months

  2. Investigate the potential specificity of the results obtained by comparing them with pain patients without fibromyalgia or nerve damage (patients with any nociceptive or nociplastic pain without fibromyalgia) matched for age and gender

    Direct group comparisons

    Time frame: Baseline and at 6 months

  3. Monitor the evolution of abnormalities obtained over time (6 months) and correlate them with the evolution of pain and associated symptoms.

    Comparison of intraepidermal nerve fiber density and other diagnostic measures between baseline and 6 months

    Time frame: 6 months

  4. Determine the sensitivity and diagnostic value of corneal confocal microscopy and laser evoked potentials as compared with skin punch biopsy for exploring nociceptive fibers

    Sensitivity and specificy of these tests compared to skin punch biopsy

    Time frame: Baseline and at 6 months

  5. Determine the diagnostic value of the sudoscan and quantified sensory tests compared with other tests for exploring nociceptive fibers in these patients

    Sensitivity and specificy of sudoscan and quantitative sensory testing compared to skin punch biopsy

    Time frame: Baseline and at 6 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Dec 2025, 47 months after the start.

Of 337 non-industry observational studies under Chronic Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 56. This study's planned 47 months is above that.

Counting every sponsor, half of 363 studies reached it within 24 months; a quarter within 12 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2024
First posted
Jul 30, 2024
StartActual
Jan 4, 2022
Primary completionEst.
Dec 2025
CompletionEst.
May 2026
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06527183
Lead sponsor
Hospital Ambroise Paré Paris
Responsible party
Nadine ATTAL (Coordinator, Hospital Ambroise Paré Paris) — Principal investigator
First posted
Jul 30, 2024
Start date
Jan 4, 2022
Primary completion
Dec 2025 (estimated)
Completion
May 2026 (estimated)
Last update
Sep 10, 2025

Study contacts

Nadine ATTAL, MD PhD
Contact
nadine.attal@aphp.fr
0033149095931
Didier BOUHASSIRA, MD PhD
Contact
didier.bouhassira@inserm.fr
0033149094556
Nadine ATTAL, MD PhD
principal investigator · APHP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion